Nath Bio-Genes (India) Limited (NATHBIOGEN) Fair Value & Analysis
Basic Materials · IN · Market cap ₹3.1B
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price −3.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹127.29 – ₹229.04 · fair‑value band ₹263.49 – ₹414.88 · the ₹164.87 price screens below the ₹289.00 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Nath Bio-Genes (India) Limited (NATHBIOGEN) currently trades at ₹164.87, while our model-based Fair Value estimate is ₹289.00 — implying the stock looks roughly 75.3% undervalued today. We read business quality at 46/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Nath Bio-Genes (India) Limited generated revenue of ₹4.5B at a net margin of 9.4%. Revenue declined 1.0% year over year. It earns a return on equity of 6.3%. Net debt stands at ₹625M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; plant nutrient supplements; pearl millets; seeds for field crops, such as bajra, maize, corn, paddy, wheat, and jowar; and seeds for vegetables comprising chilli, okra, tomato, bitter gourd, and cucumber. It also provides crop protection supplements under the Win-chi-Win, WinGoli, and WinPro Granules brands; and forage seeds under the NUTRIMAX GOLD and NUTRIMAX brand names. The company was founded in 1979 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Nath Bio-Genes (India) Limited reported revenue of ₹4.5B in FY2026 versus ₹2.8B in FY2022, a compound +12.5%/yr. Reported net income was ₹416M in FY2026.
Is NATHBIOGEN fairly valued? → Check now
Similar stocks
6 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $74.46 | $37.84 | -49% |
| Nutrien Ltd NTR | $65.03 | $50.33 | -23% |
| Qinghai Salt Lake Industry Co 000792 | ¥30.69 | ¥26.81 | -13% |
| CF Industries Holdings C1FI34 | R$533.71 | R$176.57 | -67% |
| Yara International ASA YAR | kr 502.80 | kr 695.65 | +38% |
| ICL Group ICL | $6.21 | $3.02 | -51% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Nath Bio-Genes (India) Limited (NATHBIOGEN) undervalued?
What is the fair value of NATHBIOGEN?
What is the quality score of NATHBIOGEN?
What is the revenue of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
What is the net profit margin of NATHBIOGEN?
Does Nath Bio-Genes (India) Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.